vs
爱德华生命科学(EW)与PLEXUS CORP(PLXS)财务数据对比。点击上方公司名可切换其他公司
爱德华生命科学的季度营收约是PLEXUS CORP的1.5倍($1.6B vs $1.1B),爱德华生命科学净利率更高(23.1% vs 3.8%,领先19.2%),爱德华生命科学同比增速更快(16.7% vs 9.6%),过去两年爱德华生命科学的营收复合增速更高(9.7% vs 7.9%)
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业,专注于人工心脏瓣膜及血流动力学监测领域,其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质,搭配球囊扩张式钴铬合金支架,可通过导管完成植入。
Plexus Corp是总部位于美国密歇根州特洛伊市的软件企业,专注于开发及推广Plex制造云产品,这是一款面向制造行业的SaaS模式云计算ERP解决方案,可助力制造企业实现数字化运营管理升级。
EW vs PLXS — 直观对比
营收规模更大
EW
是对方的1.5倍
$1.1B
营收增速更快
EW
高出7.1%
9.6%
净利率更高
EW
高出19.2%
3.8%
两年增速更快
EW
近两年复合增速
7.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | ||
|---|---|---|
| 营收 | $1.6B | $1.1B |
| 净利润 | $380.7M | $41.2M |
| 毛利率 | 78.0% | 9.9% |
| 营业利润率 | 1.8% | 5.1% |
| 净利率 | 23.1% | 3.8% |
| 营收同比 | 16.7% | 9.6% |
| 净利润同比 | 6.8% | -19.9% |
| 每股收益(稀释后) | $0.66 | $1.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
EW
PLXS
| Q1 26 | $1.6B | $1.1B | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
净利润
EW
PLXS
| Q1 26 | $380.7M | $41.2M | ||
| Q4 25 | $91.2M | — | ||
| Q3 25 | $291.1M | — | ||
| Q2 25 | $333.2M | — | ||
| Q1 25 | $358.0M | — | ||
| Q4 24 | $385.6M | — | ||
| Q3 24 | $3.1B | — | ||
| Q2 24 | $366.3M | — |
毛利率
EW
PLXS
| Q1 26 | 78.0% | 9.9% | ||
| Q4 25 | 78.1% | — | ||
| Q3 25 | 77.8% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 78.7% | — | ||
| Q4 24 | 78.9% | — | ||
| Q3 24 | 80.6% | — | ||
| Q2 24 | 79.9% | — |
营业利润率
EW
PLXS
| Q1 26 | 1.8% | 5.1% | ||
| Q4 25 | 9.6% | — | ||
| Q3 25 | 19.8% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 27.9% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 25.9% | — | ||
| Q2 24 | 26.8% | — |
净利率
EW
PLXS
| Q1 26 | 23.1% | 3.8% | ||
| Q4 25 | 5.8% | — | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | 21.7% | — | ||
| Q1 25 | 25.3% | — | ||
| Q4 24 | 27.8% | — | ||
| Q3 24 | 226.7% | — | ||
| Q2 24 | 26.7% | — |
每股收益(稀释后)
EW
PLXS
| Q1 26 | $0.66 | $1.51 | ||
| Q4 25 | $0.16 | — | ||
| Q3 25 | $0.50 | — | ||
| Q2 25 | $0.56 | — | ||
| Q1 25 | $0.61 | — | ||
| Q4 24 | $0.65 | — | ||
| Q3 24 | $5.13 | — | ||
| Q2 24 | $0.61 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $248.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $1.5B |
| 总资产 | — | $3.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
EW
PLXS
| Q1 26 | — | $248.8M | ||
| Q4 25 | $4.2B | — | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $3.9B | — | ||
| Q4 24 | $4.0B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $2.0B | — |
股东权益
EW
PLXS
| Q1 26 | — | $1.5B | ||
| Q4 25 | $10.3B | — | ||
| Q3 25 | $10.2B | — | ||
| Q2 25 | $10.5B | — | ||
| Q1 25 | $10.1B | — | ||
| Q4 24 | $10.0B | — | ||
| Q3 24 | $9.5B | — | ||
| Q2 24 | $7.4B | — |
总资产
EW
PLXS
| Q1 26 | — | $3.2B | ||
| Q4 25 | $13.7B | — | ||
| Q3 25 | $13.3B | — | ||
| Q2 25 | $13.5B | — | ||
| Q1 25 | $13.0B | — | ||
| Q4 24 | $13.1B | — | ||
| Q3 24 | $13.0B | — | ||
| Q2 24 | $10.1B | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EW
暂无分部数据
PLXS
| Asia-Pacific | $612.0M | 57% |
| Americas | $345.0M | 32% |
| Europe, Middle East and Africa | $118.0M | 11% |